Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT02285920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 129 participants
- Sponsor
- Registry
-
NCT02285920
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02285920. Randomized; quadruple masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2017-06 (actual). Results posted on 2019-07-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
- Acronym
- SPin-D
- Condition
- End-Stage Renal Disease
- Intervention (Drug)
- Spironolactone
- Lead sponsor
- University of Pennsylvania
- Collaborator
- Brigham and Women's Hospital
- Collaborator
- George Washington University
- Collaborator
- Vanderbilt University
- Collaborator
- University of Washington
Record details
- Record id
cardio:ct-nct02285920- Content hash
355cf37b5bf5b4fd658e3b44ed41c895f36f395f9b4fcb3f25b52061087de2cb